Actavis

Brera Holdings Signs All-Star Advisory Board to Lead Soccer World’s First Nasdaq-Listed Multi-Club Ownership Model

Retrieved on: 
Tuesday, February 27, 2024
Cloud, Senior, Pioneer, MCO, Sale, Parent, Summer Olympic Games, Premiership, Dean Witter Reynolds, Allergan, Inc., Alan, Arsenal, Bausch Health, Bear Stearns, WNBA, Happiness, Advisory board, New York Stock Exchange, The Pursuit of Happyness, World cup, Major League Soccer, Tosetti, Chairperson, Latham & Watkins, Chicago Bulls, SCF, Century Bank, Compensated emancipation, Academy Awards, Association football, Pursuit, Investment, MLS, A.C. Milan, Arsenal F.C., Actavis, Football

DUBLIN, Ireland and MILAN, Italy, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Brera Holdings PLC (“Brera Holdings”, “Brera” or the “Company”) (Nasdaq: BREA) is pleased to announce the formation of a top-tier Advisory Board to lead the world’s first publicly-traded multi-club ownership (“MCO”) company in global football (American soccer).

Key Points: 
  • DUBLIN, Ireland and MILAN, Italy, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Brera Holdings PLC (“Brera Holdings”, “Brera” or the “Company”) (Nasdaq: BREA) is pleased to announce the formation of a top-tier Advisory Board to lead the world’s first publicly-traded multi-club ownership (“MCO”) company in global football (American soccer).
  • Rothenberg was president of U.S. Soccer , the governing body of American soccer during the 1990s and oversaw both the 1994 FIFA World Cup in the United States and the establishment of Major League Soccer (“MLS”) in 1996.
  • Geller has been a member of the board of directors for numerous Nasdaq and New York Stock Exchange listed companies.
  • “Landing an all-star team to join our Advisory Board is a resounding stamp of approval for Brera’s business model.

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

Retrieved on: 
Thursday, February 8, 2024
Degree, Marketing, Senior, Abbott Laboratories, Fairleigh Dickinson University, Actavis, Novartis, Patient, Safety, FDA, IPO, Ageing, MBA, Communication, Babesiosis, Kean University, Tafenoquine, Infection, Malaria, Pharma, Business, Sprout, Pharmaceutical industry

WASHINGTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has appointed Kristen Landon to the newly created role of Chief Commercial Officer, effective immediately.

Key Points: 
  • WASHINGTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has appointed Kristen Landon to the newly created role of Chief Commercial Officer, effective immediately.
  • Ms. Landon is an accomplished commercial leader with over 26 years’ experience launching, building, and transforming commercial teams and brands in the pharmaceutical industry.
  • “We screened hundreds of applicants during the second half of 2023 and Kristen’s vision and directly relevant experience made her the ideal match for the position,” said Geoff Dow, PhD., 60 Degrees Pharma Chief Executive Officer.
  • Ms. Landon holds an MBA from Silberman College of Business at Fairleigh Dickinson University, and a Bachelor’s degree from Kean University.

Cytovation Announces Appointment of Ellen Lubman, MBA to its Board of Directors

Retrieved on: 
Wednesday, December 20, 2023
Adrenocortical carcinoma, Dentistry, DSM-IV codes, Kadmon Corporation, Corporate communication, Business, Acquisition, BIO, Large intestine, Liver, MBA, Rutgers University, Cancer, Actavis, University, Abbott Laboratories, Patient, Bristol Myers Squibb, Pharmaceutical industry

Bergen, Norway, December 20, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumour membrane immunotherapy CyPep-1, today announced the election of Ellen Lubman, MBA, to its Board of Directors.

Key Points: 
  • Bergen, Norway, December 20, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumour membrane immunotherapy CyPep-1, today announced the election of Ellen Lubman, MBA, to its Board of Directors.
  • “We are excited to welcome Ellen, who brings extensive experience and a well-proven track record across business development, finance, and fundraising in biopharma, to Cytovation’s Board,” said Stein Christian Mohn, Chairman of Cytovation.
  • Ms. Lubman has also served on the Board of Directors of Reunion Neuroscience, Inc., a privately held biotechnology company, since June 2021.
  • She also serves as an Advisor to GeneCentric Therapeutics, Inc. where she recently held a role on the Board of Directors, and TMRW.org.

CorMedix Inc. Announces Appointment of Chief Legal Officer

Retrieved on: 
Friday, December 15, 2023
Amherst College, Amneal Pharmaceuticals, FDA, Legal Affairs, Actavis, Civil Service (United Kingdom), Assistant, King Pharmaceuticals, EVP, Corporation

as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023.

Key Points: 
  • as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023.
  • Ms. Zelnick Kaufman has more than two decades of legal, compliance and operations experience in the life sciences industry.
  • Prior to joining CorMedix, she most recently served as Chief Legal and Administrative Officer and Corporate Secretary of Akorn Pharmaceuticals, a specialty and generic pharmaceuticals company.
  • “We are excited to welcome Beth to the CorMedix team at such an exciting time for the company,” said Joseph Todisco, Chief Executive Officer of CorMedix.

Lexicon Strengthens Management Team With Two New Executives

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, National Investor Relations Institute, Professional corporation, Bristol Myers Squibb, Melinta Therapeutics, Policy, AbbVie, Lexicon, Therapy, Ophthalmology, Actavis, Intercept, BS, Seton Hall University, Ozanimod, University, Amarin, Warner Chilcott, MBA, Ladenburg Thalmann, Alemtuzumab, Allergan, Business administration, Marketing, Wall Street, Watson Labs, Villalba v Merrill Lynch & Co Inc, Sclerosis, Heart failure, Intercept Pharmaceuticals, Pharmaceutical industry

THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective November 13, 2023.

Key Points: 
  • Mr. Cullen brings Lexicon more than 35 years of industry experience in market access and sales leadership.
  • Before joining Lexicon, Matt served as vice president, value, access and policy at Apellis Pharmaceuticals where he led the market access launch of rare disease drug EMPAVELI® (pegcetacoplan) and ophthalmology drug SYFOVRE® (pegcetacoplan injection).
  • His responsibilities included pricing and contracting, payer strategy and marketing, corporate and strategic account management, field reimbursement, trade and distribution, and training.
  • Prior to Apellis, Mr. Cullen led strategic payer marketing and access teams at Bristol-Myers Squibb for ELIQUIS® (apixaban) and ORENCIA® (abatacept).

Replimune Announces Appointment of Emily Hill as Chief Financial Officer

Retrieved on: 
Tuesday, September 19, 2023
Actavis, PTC Therapeutics, Senior, Fordham University, Partner, Biotechnology, PTC, MBA, Biomedical Research, Hamilton College, Summer Street (Boston), CFO, Warner Chilcott, Growth, Therapy, Financial management, Pharmaceutical industry, Management, Science, Genzyme, Finance, Pharmacology

WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer.

Key Points: 
  • WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer.
  • “Emily brings a wealth of financial planning and strategy experience to Replimune that will be impactful as we look to transition to a commercial stage company,” said Philip Astley-Sparke, CEO of Replimune.
  • “I'm looking forward to applying my expertise and experience to help Replimune continue its growth and make the transition from a clinical to commercial stage company.”
    Prior to joining Replimune, Emily held numerous positions at PTC Therapeutics where she headed up Investor Relations before becoming the Company’s Chief Financial Officer.
  • Emily was heavily involved in PTC’s evolution from a development stage company to a five product company generating revenues approaching $1billion.

Allay Therapeutics Appoints Nicole Vitullo to Board of Directors

Retrieved on: 
Wednesday, September 6, 2023
Health, Surgery, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Nicole, Actavis, University, Esperion Therapeutics, Transformation/transcription domain-associated protein, MBA, Cubist Pharmaceuticals, Onyx Pharmaceuticals, Esperies, Celgene, Partner, Patient, Forest Laboratories, Arboretum, Pain management, Alexion, Jazz Pharmaceuticals, David Allais, Mathematics, Therapy, Caregiver, Pharmaceutical industry

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.

Key Points: 
  • Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.
  • “We’re thrilled to have Nicole join the Allay board and appreciate the continued support of Arboretum Ventures as we work to change the pain management paradigm and dramatically improve the post-surgical recovery experience for patients,” said Adam Gridley, Chief Executive Officer of Allay Therapeutics.
  • Nicole currently serves on the board of Esperion Therapeutics and Hinge Bio Inc.
  • Her past board memberships include numerous companies that have entered transactions, including Achillion Pharmaceuticals (Alexion), Calixa Therapeutics (Cubist Pharmaceuticals), Celator Pharmaceuticals (Jazz Pharmaceuticals), Cerexa (Forest Laboratories), Durata Therapeutics (Actavis), Marinus Pharmaceuticals, Onyx Pharmaceuticals, and VentiRx Pharmaceuticals (Celgene).

FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market

Retrieved on: 
Wednesday, June 21, 2023
Supreme, Actavis, Laboratory, Commission, List, Supreme Court of the United Kingdom, United States Court of Appeals for the Second Circuit, Blog, Social media, Federal Trade Commission, Complaint, District court, FTC, Supreme court, Curia Julia, Douglas v. U.S. District Court ex rel Talk America, News, Federal Trade Commission v. Meta Platforms, Inc., Nebivolol

The case relates to Forest Laboratories Inc. and six generic drug manufacturers’ alleged efforts to delay competition with Bystolic, Forest’s brand-name high blood pressure drug.

Key Points: 
  • The case relates to Forest Laboratories Inc. and six generic drug manufacturers’ alleged efforts to delay competition with Bystolic, Forest’s brand-name high blood pressure drug.
  • In the Commission’s brief, the FTC urged the appeals court to reverse a district court’s decision to dismiss the case and recognize that large reverse payments Forest made to the generic companies may violate the antitrust laws.
  • Unless corrected, the district court’s ruling threatens to impair the effective enforcement of antitrust laws in the pharmaceutical industry, the FTC told the Second Circuit.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.

FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market

Retrieved on: 
Wednesday, June 21, 2023
Supreme, Actavis, Laboratory, Commission, List, Supreme Court of the United Kingdom, United States Court of Appeals for the Second Circuit, Blog, Social media, Federal Trade Commission, Complaint, District court, FTC, Supreme court, Curia Julia, Douglas v. U.S. District Court ex rel Talk America, News, Federal Trade Commission v. Meta Platforms, Inc., Nebivolol

The case relates to Forest Laboratories Inc. and six generic drug manufacturers’ alleged efforts to delay competition with Bystolic, Forest’s brand-name high blood pressure drug.

Key Points: 
  • The case relates to Forest Laboratories Inc. and six generic drug manufacturers’ alleged efforts to delay competition with Bystolic, Forest’s brand-name high blood pressure drug.
  • In the Commission’s brief, the FTC urged the appeals court to reverse a district court’s decision to dismiss the case and recognize that large reverse payments Forest made to the generic companies may violate the antitrust laws.
  • Unless corrected, the district court’s ruling threatens to impair the effective enforcement of antitrust laws in the pharmaceutical industry, the FTC told the Second Circuit.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.

Global Pharma and Biotech Clinical Stage Partnering Analysis Report 2023 with a Directory Containing Terms and Agreements for 2,900+ Deals - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 23, 2023
Health, Pharmaceutical, GSK, Amgen, Actavis, Intellectual property, Baxter, Roche, A-Z, Record, Research, Confidentiality, AstraZeneca, Eli Lilly, J&J, Biotechnology, Kyowa Kirin, Bausch Health, Novartis, Merck, Biogen, BMS, Hyperlink, Pharmaceutical industry, Commercial property, Vaccine, Risk management, Lease, Property management, Pharma, Teva, Astellas Pharma, Takeda, Bayer, Pfizer

The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023" report has been added to ResearchAndMarkets.com's offering.
  • The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023 report provides comprehensive access to available deals and contract documents for over 2,900 clinical stage deals.
  • The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.
  • Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023 includes:
    In Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023, the available contracts are listed by:
    Analyzing actual contract agreements allows assessment of the following:
    What are the precise rights granted or optioned?